Advanced Bifurcation Systems Inc.

About Advanced Bifurcation Systems Inc. Advanced Bifurcation Systems (“ABS”) is a San Francisco Bay-area medical device company pioneering the first dedicated platform for the treatment of coronary bifurcation lesions - one of the most complex and underserved challenges in interventional cardiology. The ABS System is not a stent, it’s a proprietary stent delivery system. From prototype to final product, the ABS System has been evaluated through bench testing, animal implants and 10 human implants across 3 international medical centers – all with successful results. A 6F bifurcation platform designed for automatic orientation and alignment: ~10-15 minutes for procedure completion with full lesion coverage and side-branch access. The ABS System is specifically designed to efficiently treat coronary bifurcation lesions with predictable results. The key attributes of ABS are: • $41 million raised to date, with a $20.1M Series A financing completed November 2020 and an over-subscribed $20.8M SAFE financing completed December 2024; • Institutional investors: Cedars Sinai Medical Center and Johnson & Johnson. Other investors are cardiologists, family offices and HNW individuals; • Fully developed Class III medical device with clear pathway to full FDA approval in 2027. FDA Breakthrough Device Designation received October 2023; • Fully built-out facility in San Francisco Bay area with production capacity for the first 2 years of commercialization and easily expandable; • KOL support from leading cardiologists globally • First-in-human trials completed outside of the US with 100% success rate with peer-reviewed results publications; • Intellectual property protection includes 70+ issued patents and 30+ allowed pending patents, Freedom to Operate Opinion; • In October 2024, ABS acquired all assets of a drug-eluting stent company with FDA, CE Mark and Japanese regulatory approvals in place; • Large market: ABS addresses ~20% of existing coronary stent (“PCI”) and ~20% of open-heart surgery (“CABG”) procedures. ABS will convert these procedures into a safer, faster, lower-cost procedure with better patient outcomes. The total addressable market is ~1.6 million procedures annually aggregating to ~$8+ billion and growing. The Investment opportunity is a participation in an up-to $10 million SAFE financing round followed by the remaining Series B (SAFE will convert into the Series B financing targeted for 4Q25/1Q26). The Series B financing ($35 million) will fund ABS though to full FDA approval. Exit Event is expected to be either a M&A transaction or IPO. ABS also has an office in the Dallas, Texas area.